Ketamine molecule:

Image from PubChem

Ketamine Clinical Trials

Evaluation of Efficacy and Safety of Levetiracetam, Lacosamide and Ketamine as Adjunctive Treatment of Refractory Status Epilepticus

To see complete record on, please visit this link

Id: NCT02726867

Organisation Name: Mid-Atlantic Epilepsy and Sleep Center, LLC

Overal Status: Withdrawn

Start Date: February 2014

Last Update: August 29, 2017

Lead Sponsor: Mid-Atlantic Epilepsy and Sleep Center, LLC

Brief Summary: The purpose of the study is to evaluate the efficacy and safety of levetiracetam , lacosamide and ketamine treatment of refractory status epilepticus. This will be a randomized, open-label, four-arm pilot study comparing time to cessation of refractory status epilepticus, determined by continuous EEG monitoring, in patients with refractory status epilepticus. Patients with status epilepticus who have been treated with standard dose lorazepam (or midazolam) and ≥ 1000 mg phenytoin with documented levels of ≥20 mg/ml and continue to have clinical status epilepticus for ≥1-24 hours after phenytoin loading will receive intravenously (i.v.) either 4000 mg levetiracetam, 600 mg lacosamide (Group B), 2.5 mg/kg ketamine or phenobarbital 15 mg/kg phenobarbital (Group D)

  • Epilepsy
  • Status Epilepticus

Total execution time in seconds: 0.20522809028625